Case Reports

Myasthenic syndrome in systemic lupus erythematosus successfully treated with plasma exchange: through one of the unexplored faces of neuropsychiatric involvement

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 8 April 2026
149
Views
32
Downloads

Authors

Neuropsychiatric systemic lupus erythematosus (NPSLE) encompasses a wide range of neurological manifestations, including, though rarely, myasthenia gravis (MG). We report the case of a 47-year-old woman with long-standing SLE who developed diplopia and fluctuating muscle weakness. Electromyography revealed a decremental response to low-frequency stimulation in the absence of MG-specific autoantibodies. These neurological features were interpreted as manifestations of NPSLE and were initially treated with azathioprine and then rituximab, the latter discontinued due to an adverse reaction. Several years later, immunosuppressive therapy with mycophenolate mofetil and voclosporin was initiated following a renal flare. Although renal remission was achieved, the patient experienced a concomitant relapse of neurological symptoms. After multidisciplinary consultation with neurologists, the patient underwent three monthly cycles of plasma exchange combined with corticosteroid pulses, resulting in marked clinical improvement of neurologic symptoms and sustained serological and clinical stability during the follow-up. The coexistence of SLE and MG is uncommon; distinguishing between an overlap syndrome or lupus-related myasthenic manifestations and choosing the optimal therapeutic strategy remain challenging. In this case, plasma exchange proved to be an effective rescue therapy, highlighting the importance of a multidisciplinary approach and individualized treatment strategies in managing complex NPSLE presentations.

Downloads

Download data is not yet available.

Citations

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
Kivity S, Agmon-Levin N, Zandman-Goddard G, Chapman J, Shoenfeld Y. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 2015; 13: 43.
Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Systemic Lupus International Collaborating Clinics (SLICC). Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69: 529-35.
Toledano P, Orueta R, Rodríguez-Pintó I, Valls-Solé J, Cervera R, Espinosa G. Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. Autoimmun Rev 2017; 16: 750-5.
Minchenberg SB, Chaparala G, Oaks Z, Banki K, Perl A. Systemic lupus erythematosus-myasthenia gravis overlap syndrome: Presentation and treatment depend on prior thymectomy. Clin Immunol 2018; 194: 100-4.
Castrejón I, Shum K, Tseng CE, Askanase A. Association between myasthaenia gravis and systemic lupus erythematosus: three case reports and review of the literature. Scand J Rheumatol 2011; 40: 486-90.
Jallouli M, Saadoun D, Eymard B, Leroux G, Haroche J, Le Thi Huong D, et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol 2012; 259: 1290-7.
Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475-90.
Gilhus NE. Myasthenia gravis. N Engl J Med 2016; 375: 2570-81.
Igoe A, Merjanah S, Harley ITW, Clark DH, Sun C, Kaufman KM, et al. Association between systemic lupus erythematosus and myasthenia gravis: a population-based National Study. Clin Immunol 2024; 260: 109810.
Bortoluzzi A, Scirè CA, Bombardieri S, Caniatti L, Conti F, De Vita S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology 2015; 54: 891-8.
Manca E. Autoantibodies in neuropsychiatric systemic lupus erythematosus (NPSLE): can they be used as biomarkers for the differential diagnosis of this disease? Clin Rev Allergy Immunol 2022; 63: 194-209.
Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 2023; 16: 17562864231213240.
García-Alfonso C, Bernal-Macías S, García-Pardo Y, Millán SP, Díaz MC. Coexistence of systemic lupus erythematosus and myasthenia gravis: an unusual case of polyautoimmunity. Reumatol Clin 2020; 16: 502-5.
Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the American Society for Apheresis: the ninth special issue. J Clin Apher 2023; 38: 77-278.

How to Cite



1.
Myasthenic syndrome in systemic lupus erythematosus successfully treated with plasma exchange: through one of the unexplored faces of neuropsychiatric involvement. Reumatismo [Internet]. 2026 Apr. 8 [cited 2026 Apr. 17];. Available from: https://www.reumatismo.org/reuma/article/view/1956